AMendment 1 to LICENSE AND TRANSITION SERVICES AGREEMENTLicense and Transition Services Agreement • August 1st, 2023 • Rigel Pharmaceuticals Inc • Pharmaceutical preparations
This AMENDMENT 1 to the License and Transition Services Agreement by and between Rigel Pharmaceuticals, Inc. (the “Company”) and Forma Therapeutics, Inc. (“Forma”) dated July 27, 2022 (the “Agreement”) is made and entered into this 22nd day of December 2022 (the “Amendment”).
LICENSE AND transition services AGREEMENT by and between RIGEL PHARMACEUTICALS, INC., and Forma Therapeutics, Inc. July 27, 2022License and Transition Services Agreement • November 3rd, 2022 • Rigel Pharmaceuticals Inc • Pharmaceutical preparations • New York
THIS LICENSE AND Transition services AGREEMENT (this “Agreement”), entered into as of July 27, 2022 (the “Effective Date”), is entered into by and between Rigel Pharmaceuticals, Inc., a corporation organized and existing under the laws of the state of Delaware (“Company”), and Forma Therapeutics, Inc. a corporation organized and existing under the laws of the state of Delaware (“Forma”).
